Press Release Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma 3 minutes ago
Press Release Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock 1 hour ago
Press Release Litchfield Hills Research Reiterates Buy Rating and $66 Price Target; Faraday Future Global CEO YT Jia and the Founding Team Affirm Their Commitment to Long-Term Share Ownership 2 hours ago
Press Release Nebius Group announces pricing of upsized private offering of $5.0 billion of convertible senior notes 2 hours ago
Press Release New AI Safety Council Brings Technology and Domestic Violence Experts Together to Advance Responsible AI Innovation 2 hours ago
Press Release Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma 2 hours ago
Press Release Limbic Becomes First AI-Led Mental Healthcare Company Selected for FDA TEMPO 2 hours ago
Press Release Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner 2 hours ago
Press Release Williams-Sonoma, Inc. announces release date for second quarter results: Wednesday, August 26th, 2026 2 hours ago
Press Release WIX INVESTOR REMINDER: Wix.com Ltd. Investors Have Until September 22, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role 2 hours ago